We are Healthy
U.S.

COPD Drug Tozorakimab Reduced Exacerbations in Trials

A new monoclonal antibody showed promise in lowering flare-ups for patients living with chronic obstructive pulmonary disease.

Updated on Oct. 4, 2026 in Asthma

Bold flat-color editorial illustration showing stylized, interconnected geometric lung structures and molecular bonds, representing pharmaceutical progress in respiratory treatment.
In phase 3 clinical trials, the monoclonal antibody tozorakimab significantly reduced moderate-to-severe exacerbations in patients managing chronic obstructive pulmonary disease. AI Illustration. Upload story photo >

Live Poll

Do you believe new medical breakthroughs are effectively improving long-term health outcomes for chronic patients?

In phase 3 trials announced in March 2026, the investigational drug tozorakimab demonstrated a reduction in moderate-to-severe COPD exacerbations for patients with a history of smoking. This development potentially offers a new therapeutic pathway for individuals managing symptomatic COPD.

Why it matters

Reducing exacerbations is a key goal in COPD management, as these flare-ups often lead to hospitalizations and long-term lung function decline. By targeting inflammation, this drug could change how clinicians stabilize patients who are prone to frequent respiratory complications.

In the OBERON and TITANIA phase 3 trials involving 2,306 symptomatic patients, tozorakimab showed varying efficacy based on blood eosinophil levels. Researchers observed a 43% reduction in exacerbations for those with counts of at least 300 cells/µL, compared to a 23% reduction for those below 150 cells/µL.

The players

AstraZeneca

A pharmaceutical company that researches and manufactures treatments for respiratory, cardiovascular, and oncological conditions.

FDA

The federal agency responsible for protecting public health by regulating the safety and efficacy of pharmaceuticals.

The details

Tozorakimab is a monoclonal antibody that inhibits interleukin-33 signaling. By blocking this specific pathway, the treatment works to mitigate systemic inflammation and address the mucus dysfunction that contributes to airway obstruction in COPD patients. Participants in the 52-week study received 300mg doses of the drug or a placebo every four weeks.

Timeline

  1. AstraZeneca announced trial results in March 2026.

  2. The findings were reported on October 4, 2026.

Health Landscape

Tozorakimab sits within a growing class of biologics aiming to personalize COPD care by targeting specific inflammatory markers like interleukin-33. This marks a shift from broad-spectrum maintenance therapies toward treatments tailored to a patient's underlying biological profile.

If you manage COPD, these results illustrate how blood biomarkers may soon help doctors better predict which therapies will be most effective for you. Discuss the potential for biologic-based treatments with your pulmonologist during your next review of your chronic care management plan.

The takeaway

Targeting interleukin-33 represents a promising biological approach to reducing the frequency of severe respiratory flare-ups. Speak with your physician about how newer specialized therapies might eventually fit into your existing lung health maintenance routine.

Further reading

For more on managing airway inflammation, visit the Asthma section.

Source note: This article includes information reported by Pharmafile.

Live Poll

Do you believe new medical breakthroughs are effectively improving long-term health outcomes for chronic patients?